Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.